EMA MR: long half life → MD [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2020-08-09 12:08 (208 d 06:06 ago) – Posting: # 21843
Views: 1,117

Hi Loky do,

» […] solifenacin 6 mg (immediate-release) / tamsulosin 0.4 mg modified-release product combination, is multiple-dose bioequivalence study required to be submitted to the European authorities in addition to fast & fed studies,

Yes, since due to their long half lives waiving of the multiple dose study will not be possible (see this post). Given the half life of tamsulosin the MD study will be nasty.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,368 posts in 4,462 threads, 1,494 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Friday 17:15 CET (Europe/Vienna)

The statistician has no magic touch by which
he may come in at the stage of tabulation
and make something of nothing.    W. Edwards Deming

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz